Nirmatrelvir treatment duration and frequency of COVID-19 rebound
These findings suggest that a longer nirmatrelvir/ritonavir course might reduce rebound symptoms compared to the standard 5-day regimen.
Authors
- Noah Kojima (ORCID: https://orcid.org/0000-0002-3667-9719)
- Jeffrey David Klausner (ORCID: https://orcid.org/0000-0002-6922-7364)
- Nathan Sudeep (ORCID: https://orcid.org/0009-0008-1933-7996)
Institutions
- University of Southern California (US)
Publication Details
- Journal
- Antiviral Therapy
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1177/13596535251323728
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00